Abstract
Although it has been difficult to control severe and intractable asthma patients, even adults, using conventional therapy, a new treatment featuring regular use of DSCG and salbutamol inhalation produced an improvement in the clinical symptoms and the quality of life for almost all patients with asthma.
When the clinical symptoms for 3 months before regular use were compared with those for three months after use, asthma attack scores for severe and intractable patients decreased from 22.8 to 10.2, and from 71.7 to 17.4, respectively.
Frequency of emergency room visits decreased from 12.3 to 3.1 times in 12 severe patients and from 27.3 to 1.1 times in 7 intractable patients. Mean dosage of corticosteroid (prednisolone) for intractable patients decreased from 460.7mg (range 150 to 945mg) to 74.2mg (range 0 to 415mg).
It is concluded that the regular use of DSCG and a β2 agonist not only prevented asthmatic attacks, but also induced an improvement in intractable patients by prolonging bronchodilatation, inhibiting the effect against bronchial inflammation and reducing bronchial hypersensitivity.
